TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39585696

Group type: EXPERIMENTAL
Intervention: Centralized CRC screening outreach intervention (mailed fecal immunochemical testing and patient navigation)
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy after positive FIT results
Number of subjects: 4002

Group type: EXPERIMENTAL
Intervention: Detection of advanced colorectal neoplasia
Number of subjects: 4002
Study: 39585770

Group type: EXPERIMENTAL
Intervention: Patients with cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intimate partner family caregivers
Number of subjects: 0
Study: 39585776

Group type: EXPERIMENTAL
Intervention: AgingPLUS program, a 4-week psychoeducational intervention
Number of subjects: 0
Study: 39585851

Group type: EXPERIMENTAL
Intervention: Revi System (implantable tibial neuromodulation)
Number of subjects: 151
Study: 39585879

Group type: EXPERIMENTAL
Intervention: CENBA programme (mHealth psychoeducational intervention)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study: 39585936

Group type: EXPERIMENTAL
Intervention: Cilostazol (50 or 100 mg, twice per day) added to other antiplatelets
Number of subjects: 631

Group type: COMPARATOR
Intervention: Non-cilostazol (no cilostazol added)
Number of subjects: 631
Study: 39586017

Group type: EXPERIMENTAL
Intervention: Four Supports intervention (emotional support, communication support, decisional support, anticipatory grief support)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Usual care plus two brief education sessions about critical illness (Control)
Number of subjects: 444
Study: 39586038

Group type: EXPERIMENTAL
Intervention: Alkylating agents (ALKY)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Oxaliplatin (Ox)
Number of subjects: 105
Study: 39586304

Group type: EXPERIMENTAL
Intervention: Cenerimod 4.0 mg
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Cenerimod 2.0 mg
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Cenerimod 1.0 mg
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Cenerimod 0.5 mg
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 39586309

Group type: EXPERIMENTAL
Intervention: No-radioiodine group
Number of subjects: 776

Group type: COMPARATOR
Intervention: Radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone)
Number of subjects: 776
Study: 39586354

Group type: EXPERIMENTAL
Intervention: PRC-CM intervention with multifaceted implementation strategy package including comprehensive training, individual clinical supervision, group consultation, and centralized technical assistance
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Technical assistance strategy
Number of subjects: 8
Study: 39586616

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) plus azathioprine (AZA) with a 7-day steroid tapering scheme
Number of subjects: 64

Group type: COMPARATOR
Intervention: Azathioprine (AZA) with conventional standardised steroid tapering regimen
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both arms (IFX+AZA and AZA)
Number of subjects: 64
Study: 39586754

Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion or removal (LAAO) during cardiac surgery
Number of subjects: 4811
Study: 39587050

Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan (T-DXd)
Number of subjects: 53
Study: 39587506

Group type: EXPERIMENTAL
Intervention: Provider advice about gestational weight gain (GWG)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Expectations about GWG
Number of subjects: 377
Study: 39587504

Group type: EXPERIMENTAL
Intervention: Neurocognitive Adaptive Training for Depression (NCAT-D) combined with SSRIs
Number of subjects: 118

Group type: COMPARATOR
Intervention: SSRIs with Control treatment
Number of subjects: 118
Study: 39587538

Group type: EXPERIMENTAL
Intervention: High-frequency deep brain stimulation (DBS) applied to bilateral ventral hippocampus for 3 months
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation for 3 months
Number of subjects: 6
Study: 39587593

Group type: EXPERIMENTAL
Intervention: SRP + Ozone
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 24
Study: 39587600

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 206

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 206
Study: 39587610

Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Home (CP@home) program
Number of subjects: 2284

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 2284
Study: 39587622

Group type: EXPERIMENTAL
Intervention: High-concentration platelet-rich plasma (PRP) injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (placebo) injection
Number of subjects: 90
Study: 39587799

Group type: EXPERIMENTAL
Intervention: High protein breakfast (34 g protein)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Low protein breakfast
Number of subjects: 56
Study: 39587796

Group type: EXPERIMENTAL
Intervention: Tegoprazan (50 mg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg)
Number of subjects: 218
Study: 39587825

Group type: EXPERIMENTAL
Intervention: Extended DAPT (75 mg clopidogrel plus 75-150 mg aspirin daily)
Number of subjects: 8250

Group type: COMPARATOR
Intervention: Monotherapy (75-150 mg aspirin daily)
Number of subjects: 8250
Study: 39587915

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice a week for 4 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional rehabilitation program (control group)
Number of subjects: 54
Study: 39587931

Group type: EXPERIMENTAL
Intervention: PVRV-NG2 (three-dose regimen)
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: PVRV-NG2 (two-dose regimen)
Number of subjects: 1708

Group type: COMPARATOR
Intervention: HDCV (three-dose regimen)
Number of subjects: 1708

Group type: COMPARATOR
Intervention: PVRV (three-dose regimen)
Number of subjects: 1708
Study: 39588043

Group type: EXPERIMENTAL
Intervention: Ketogenic diet supplemented with exogenous ketones for 4 weeks
Number of subjects: 4
Study: 39588067

Group type: EXPERIMENTAL
Intervention: Cryoballoon-ablation of AF
Number of subjects: 102
Study: 39588126

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) immediately after childbirth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived parental stress 6 months after discharge
Number of subjects: 0
Study: 39588131

Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (ibandronate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39588189

Group type: EXPERIMENTAL
Intervention: Yijinjing exercise (YJJG), conducted three times per week over a 12-week period
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Yijinjing exercise (YJJG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CG), maintained ordinary activities
Number of subjects: 66
Study: 39588212

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: General neurocognitive outcomes
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ototoxicity
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Chronic medical conditions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Congenital malformations
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Attention-Deficit Hyperactivity Disorder
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Extra neurocognitive support
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Overall health outcomes
Number of subjects: 144
Study: 39588375

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 5280
Study: 39588662

Group type: EXPERIMENTAL
Intervention: Workload measured by electronic note count
Number of subjects: 2318

Group type: EXPERIMENTAL
Intervention: Years since training
Number of subjects: 2318
Study: 39588974

Group type: EXPERIMENTAL
Intervention: EsoGuard (EG) assay on samples collected nonendoscopically with the EsoCheck (EC) device
Number of subjects: 180

Group type: COMPARATOR
Intervention: EsoGuard (EG) assay
Number of subjects: 180
Study: 39588987

Group type: EXPERIMENTAL
Intervention: ADS051 1,500 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All dose groups of ADS051
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ADS051
Number of subjects: 50
Study: 39589133

Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 25 mg (n = 51)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 50 mg (n = 52)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Complex ART regimen (n = 25)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 25 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BIC 75 mg + LEN 50 mg
Number of subjects: 128

Group type: COMPARATOR
Intervention: Complex ART regimen
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: BIC + LEN (both dosing regimens)
Number of subjects: 128
Study: 39589151

Group type: EXPERIMENTAL
Intervention: Influenza A/Perth/16/2009 (H3N2) virus
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study: 39589250

Group type: EXPERIMENTAL
Intervention: Intraprocedural percutaneous US volume flow (VF) measurements before and after balloon dilation.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Postprocedural VF measurements after angioplasty.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher VF at completion of angioplasty.
Number of subjects: 100
Study: 39589296

Group type: EXPERIMENTAL
Intervention: Myval THV series
Number of subjects: 768
Study: 39589314

Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS) with 2 mL sulfur hexafluoride lipid-type A microspheres (Lumason) per lesion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS) for lesions ≥ 2 cm
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hepatobiliary agent MRI (HBA-MRI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hepatobiliary agent MRI (HBA-MRI) for lesions ≥ 2 cm
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for all lesions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for lesions ≥ 2 cm
Number of subjects: 40
Study: 39589370

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 592

Group type: COMPARATOR
Intervention: Standard lymphadenectomy
Number of subjects: 592
Study: 39589559

Group type: EXPERIMENTAL
Intervention: Smartphone-based virtual reality relaxation (SVR)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (standard care and guided imagery leaflets)
Number of subjects: 99
Study: 39589664

Group type: EXPERIMENTAL
Intervention: Alendronate solution (ALN-S)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Alendronate tablet (ALN-T)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both ALN-S and ALN-T
Number of subjects: 170
Study: 39589666

Group type: EXPERIMENTAL
Intervention: Generic nab-paclitaxel monotherapy
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Generic nab-paclitaxel-based combination therapy
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Combination therapy with ≥ 4 treatment cycles
Number of subjects: 1168
Study: 39589672

Group type: EXPERIMENTAL
Intervention: Fluorine-18-labeled fluoroethyltyrosine
Number of subjects: 33
Study: 39589690

Group type: EXPERIMENTAL
Intervention: Tarlatamab (0.003, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, and 100 mg) administered every 2 weeks (Q2W) with a step dose regimen starting at 3 mg; infused over 1 hour.
Number of subjects: 203
Study: 39589722

Group type: EXPERIMENTAL
Intervention: Synchronous exercise group (n=22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Asynchronous exercise group (n=22)
Number of subjects: 44
Study: 39589719

Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Number of subjects: 0
Study: 39589721

Group type: EXPERIMENTAL
Intervention: Nurse-delivered brief behavioral treatment for insomnia (BBTI)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Healthy eating attention control group
Number of subjects: 132
Study: 39589730

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapies
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cancer remission
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sustained cancer activity
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sustained DM activity
Number of subjects: 73
Study: 39589786

Group type: EXPERIMENTAL
Intervention: Mobile app-based behavioral intervention (DRIVEN) for job seekers over 6 weeks, including scheduled video counseling sessions with a job coach.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Job seeking as usual (control group).
Number of subjects: 150
Study: 39589824

Group type: EXPERIMENTAL
Intervention: gp42-IgG antibody titers
Number of subjects: 75481
Study: 39590165

Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexamethasone (Len/Dex) followed by Donor Lymphocyte Infusions (DLIs)
Number of subjects: 22
Study: 39590221

Group type: EXPERIMENTAL
Intervention: High-fatigue leg extension exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fatigue leg extension exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (quiet rest)
Number of subjects: 0
Study: 39590559

Group type: EXPERIMENTAL
Intervention: Stair-climbing exercise (STAIR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Machine-based resistance training (RT)
Number of subjects: 46
Study: 39591190

Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta vaccine
Number of subjects: 60
Study: 39591365

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived regenerative cells (ADRCs) (4.20×10^7 ± 1.75×10^7 cells) and 30-cc lipotransfer
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived regenerative cells (ADRCs) and lipotransfer
Number of subjects: 80
Study: 39591420

Group type: EXPERIMENTAL
Intervention: Medication Coordinator intervention with medication review and suggested amendments documented in electronic discharge letter sent to GP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care by ward staff
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Medication Coordinator intervention
Number of subjects: 70
Study: 39591454

Group type: COMPARATOR
Intervention: Albendazole alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole plus ivermectin
Number of subjects: 0
Study: 39591551

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg once daily plus Pembrolizumab 200 mg once every 3 weeks
Number of subjects: 842

Group type: COMPARATOR
Intervention: Chemotherapy (Paclitaxel 175 mg/m2)
Number of subjects: 842
Study: 39591972

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study: 39592015

Group type: EXPERIMENTAL
Intervention: Electronic media use
Number of subjects: 441
Study: 39592213

Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol (PEth) measurement for alcohol use stratification
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Alcohol consumption of two or more standard drinks per day
Number of subjects: 355
Study: 39592214

Group type: EXPERIMENTAL
Intervention: Arthroscopic hip surgery
Number of subjects: 222

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 222
Study: 39592365

Group type: EXPERIMENTAL
Intervention: Driving pressure-limiting strategy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Low PEEP strategy
Number of subjects: 198
Study: 39592468

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (including L. rhamnosus DSM 32550, Humiome® L. plantarum DSM 34532, B. lactis DSM 32269, B. longum DSM 32946, fructooligosaccharides and zinc)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 39592501

Group type: EXPERIMENTAL
Intervention: Diagnostic imaging study for detection rates in early BCR of prostate cancer after radical surgery or radiotherapy.
Number of subjects: 50
Study: 39592514

Group type: EXPERIMENTAL
Intervention: High resuscitation table positioning
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low resuscitation table positioning
Number of subjects: 28
Study: 39592547

Group type: EXPERIMENTAL
Intervention: FIL200 (200 mg once daily)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: FIL100 (100 mg once daily)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg biweekly)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 39592624

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 0
Study: 39592626

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (AIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venom allergy patients (VAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pollen-allergic and healthy controls
Number of subjects: 0
Study: 39592888

Group type: EXPERIMENTAL
Intervention: BAT4406F (escalated doses ranging from 20 to 750 mg)
Number of subjects: 15
Study: 39593072

Group type: EXPERIMENTAL
Intervention: RUTF plus prebiotics
Number of subjects: 174

Group type: COMPARATOR
Intervention: RUTF plus starch
Number of subjects: 174

Group type: COMPARATOR
Intervention: Starch as placebo
Number of subjects: 174
Study: 39593091

Group type: EXPERIMENTAL
Intervention: Carrageenan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 39593101

Group type: EXPERIMENTAL
Intervention: Robotics-assisted therapy (RAT) at home for 30 consecutive days after 2 therapist-supervised clinic onboarding sessions.
Number of subjects: 12
Study: 39593191

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tamoxifen 2.5 mg
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 39593197

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal sleep night
Number of subjects: 20
Study: 39593225

Group type: EXPERIMENTAL
Intervention: Qigong Wuqinxi exercise for 50 minutes three times a week for 12 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal daily routine (control group)
Number of subjects: 63
Study: 39593435

Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: SUS group (control)
Number of subjects: 62
Study: 39593477

Group type: EXPERIMENTAL
Intervention: Intradialytic aerobic exercise on an adapted stationary exercise bike, three times per week for three months.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (without exercise) during the first three months, then switched to exercise after washout period.
Number of subjects: 33
Study: 39593519

Group type: EXPERIMENTAL
Intervention: Newly diagnosed hyperthyroidism (NDH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Euthyroid state
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 16
Study: 39593526

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Occlusal appliance
Number of subjects: 60
Study: 39593537

Group type: EXPERIMENTAL
Intervention: Cervical therapy protocol + active cervical postural treatment for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active cervical postural treatment for 4 weeks
Number of subjects: 0
Study: 39593541

Group type: EXPERIMENTAL
Intervention: Reformer Pilates exercise (6-week program, 45 min/twice per week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 44
Study: 39593566

Group type: EXPERIMENTAL
Intervention: Feldenkrais method (16 sessions of sensorimotor training)
Number of subjects: 44
Study: 39594812

Group type: EXPERIMENTAL
Intervention: Roflumilast in combination with R-CHOP (Ro+R-CHOP)
Number of subjects: 0
Study: 39595811

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39595863

Group type: EXPERIMENTAL
Intervention: Anodic tDCS combined with motor activity (MotA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Anodic tDCS combined with cognitive activity (CogA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tDCS combined with motor activity (MotS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tDCS combined with cognitive activity (CogS)
Number of subjects: 23
Study: 39596792

Group type: EXPERIMENTAL
Intervention: Inhaled Colistin via nebulizer type A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled Colistin via nebulizer type B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39597902

Group type: EXPERIMENTAL
Intervention: Tunnel Technique and Subepithelial Connective Tissue Graft with Cross-Linked Hyaluronic Acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tunnel Technique and Subepithelial Connective Tissue Graft without Cross-Linked Hyaluronic Acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39599585

Group type: EXPERIMENTAL
Intervention: Calcifediol 75 µg
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Calcifediol 100 µg
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 39599686

Group type: EXPERIMENTAL
Intervention: Carnosine supplementation (2 g/day for 14 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 39599724

Group type: EXPERIMENTAL
Intervention: Multi-component nutritional intervention combining digital interactive tools, hands-on educational materials, and healthy snacks
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 480
Study: 39599745

Group type: EXPERIMENTAL
Intervention: Prolonged Water-Only Fasting followed by a Whole-Plant-Food Diet
Number of subjects: 0